Background Cytomegalovirus (CMV) can cause severe infections in transplanted patients.
To prevent CMV infection, most liver centers use prophylaxis for CMV-seronegative …

Clinical practice guidelines recommend antiviral prophylaxis to cytomegalovirus (CMV)
donor‐positive/recipient‐negative (D+/R−) liver transplant recipients. We assessed the …

Purpose The purpose of this study was to compare the safety and efficacy of two
valganciclovir (VGCV) institutional dosing protocols for cytomegalovirus (CMV) prophylaxis …

Optimal measures for the prevention of cytomegalovirus (CMV) in high‐risk orthotopic liver
transplant (OLT) patients are unknown. The charts of high‐risk OLT recipients with 12 …

Background Cytomegalovirus (CMV) remains the leading viral cause of disease following
orthotopic liver transplantation (OLT) despite the availability of antiviral agents for …

Liver transplantation recipients (LTRs) who are seropositive for cytomegalovirus
(CMV)(recipient seropositive [R+]) are at intermediate risk for CMV disease. A preventative …

Background Cytomegalovirus (CMV) is a common opportunistic infection in patients after
liver transplant (LT). Guidelines recommend 900 mg daily of valganciclovir; however …

Context Cytomegalovirus (CMV) is an opportunistic infection that causes profound morbidity
and mortality after orthotopic liver transplant (OLT). The CMV immunoglobulin G …

Cytomegalovirus (CMV) is the most common viral pathogen that negatively impacts on the
outcome of liver transplantation. CMV cause febrile illness often accompanied by bone …

Objectives: Cytomegalovirus (CMV) infection is responsible for significant morbidity and
mortality among solid organ transplant recipients. Prophylaxis using valganciclovir (VGCV) …